TransMedics Group, Inc. (TMDX)
82.24
-2.63
(-3.10%)
USD |
NASDAQ |
Sep 01, 16:00
82.30
+0.06
(+0.07%)
After-Hours: 20:00
TransMedics Group Research and Development Expense (Annual) : 69.06M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 69.06M |
| December 31, 2024 | 55.97M |
| December 31, 2023 | 36.06M |
| December 31, 2022 | 26.81M |
| December 31, 2021 | 22.30M |
| Date | Value |
|---|---|
| December 31, 2020 | 18.55M |
| December 31, 2019 | 19.65M |
| December 31, 2018 | 13.66M |
| December 31, 2017 | 14.96M |
| December 31, 2016 | 15.64M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Alphatec Holdings, Inc. | 76.27M |
| Artivion, Inc. | 30.99M |
| Insulet Corp. | 301.10M |
| Teleflex, Inc. | 144.78M |
| Globus Medical, Inc. | 146.94M |